Close Menu

tumor mutational burden

A TMB-high cutoff of 10 mutations per megabase doesn't predict immunotherapy responses universally well across cancer types, according to a paper published in JAMA Oncology.

The new consortium is aiming to make comprehensive genomic profiling accessible to advanced cancer patients in the US, to help inform their treatment decisions.

The test will use a blood-based biopsy to detect patients with BRCA1, BRCA2, and/or ATM alterations in metastatic castration-resistant prostate cancer.

Stanford and Memorial Sloan Kettering researchers have developed a multi-modal and multi-timepoint biomarker approach to predict therapeutic benefit in lung cancer cases.

In two studies at ESMO, researchers demonstrated the ability of combined biomarker approaches to predict the efficacy of immune checkpoint inhibitors.

A consortium convened by Friends of Cancer Research has made progress in quantifying sources of TMB assay discordance and created a new test-alignment software tool.

The updated guidelines now also highlight the use of PCR and next-generation sequencing to determine microsatellite instability. 

Along with significantly mutated genes across cutaneous melanoma cases, researchers saw loss-of-function mutations in the X chromosome gene DDX3X in tumors from male patients.

The accelerated approval is based on data showing that refractory cancer patients with TMB of at least 10 mutations/Mb saw tumor shrinkage and had durable responses on the immunotherapy.

In a retrospective study, investigators saw a survival benefit among head and neck cancer patients with high TMB treated with checkpoint inhibitors. 

Pages

Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Science reports that a Dutch research funding agency is combating a ransomware attack.

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.